10 results on '"Dunn GP"'
Search Results
2. Considerations for personalized neoantigen vaccination in Malignant glioma.
- Author
-
Dunn GP, Sherpa N, Manyanga J, and Johanns TM
- Subjects
- Antigens, Neoplasm, Humans, Immunologic Factors, Immunotherapy, Vaccination, Cancer Vaccines therapeutic use, Glioblastoma drug therapy, Glioma drug therapy, Neoplasms drug therapy
- Abstract
Malignant gliomas are the most common primary brain cancer diagnosed and still carry a poor prognosis despite aggressive multimodal management. Despite the continued advances in immunotherapy for other cancer types, however, there remain no FDA approved immunotherapies for cancers such as glioblastoma. OF the many approaches being explored, cancer vaccine programs are undergoing a renaissance due to the technological advances and personalized nature of their contemporary design. Neoantigen vaccines are a form of immunotherapy involving the use of DNA, mRNA, and proteins derived from non-synonymous mutations identified in patient tumor tissue samples to stimulate tumor-specific T-cell reactivity leading to enhance tumor targeting. In the last several years, the study of neoantigens as a therapeutic target has increased, with the routine workflow implementation of comprehensive next generation sequencing and in silico peptide binding prediction algorithms. Several neoantigen vaccine platforms are being evaluated in clinical trials for malignancies including melanoma, pancreatic cancer, breast cancer, lung cancer, and glioblastoma, among others. In this review, we will review the concept of neoantigen discovery using cancer immunogenomics approaches in glioblastoma and explore the disease-specific issues being addressed in the design of effective personalized cancer vaccine strategies., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
3. Impact of Intraoperative Magnetic Resonance Imaging and Other Factors on Surgical Outcomes for Newly Diagnosed Grade II Astrocytomas and Oligodendrogliomas: A Multicenter Study.
- Author
-
Yahanda AT, Patel B, Shah AS, Cahill DP, Sutherland G, Honeycutt J, Jensen RL, Rich KM, Dowling JL, Limbrick DD, Dacey RG, Kim AH, Leuthardt EC, Dunn GP, Zipfel GJ, Leonard JR, Smyth MD, Shah MV, Abram SR, Evans J, and Chicoine MR
- Subjects
- Adolescent, Adult, Aged, Brain Neoplasms mortality, Child, Child, Preschool, Female, Glioma mortality, Humans, Kaplan-Meier Estimate, Middle Aged, Neuroimaging methods, Neurosurgical Procedures mortality, Progression-Free Survival, Retrospective Studies, Surgery, Computer-Assisted mortality, Young Adult, Brain Neoplasms surgery, Glioma surgery, Magnetic Resonance Imaging methods, Neurosurgical Procedures methods, Surgery, Computer-Assisted methods
- Abstract
Background: Few studies use large, multi-institutional patient cohorts to examine the role of intraoperative magnetic resonance imaging (iMRI) in the resection of grade II gliomas., Objective: To assess the impact of iMRI and other factors on overall survival (OS) and progression-free survival (PFS) for newly diagnosed grade II astrocytomas and oligodendrogliomas., Methods: Retrospective analyses of a multicenter database assessed the impact of patient-, treatment-, and tumor-related factors on OS and PFS., Results: A total of 232 resections (112 astrocytomas and 120 oligodendrogliomas) were analyzed. Oligodendrogliomas had longer OS (P < .001) and PFS (P = .01) than astrocytomas. Multivariate analyses demonstrated improved OS for gross total resection (GTR) vs subtotal resection (STR; P = .006, hazard ratio [HR]: .23) and near total resection (NTR; P = .02, HR: .64). GTR vs STR (P = .02, HR: .54), GTR vs NTR (P = .04, HR: .49), and iMRI use (P = .02, HR: .54) were associated with longer PFS. Frontal (P = .048, HR: 2.11) and occipital/parietal (P = .003, HR: 3.59) locations were associated with shorter PFS (vs temporal). Kaplan-Meier analyses showed longer OS with increasing extent of surgical resection (EOR) (P = .03) and 1p/19q gene deletions (P = .02). PFS improved with increasing EOR (P = .01), GTR vs NTR (P = .02), and resections above STR (P = .04). Factors influencing adjuvant treatment (35.3% of patients) included age (P = .002, odds ratio [OR]: 1.04) and EOR (P = .003, OR: .39) but not glioma subtype or location. Additional tumor resection after iMRI was performed in 105/159 (66%) iMRI cases, yielding GTR in 54.5% of these instances., Conclusion: EOR is a major determinant of OS and PFS for patients with grade II astrocytomas and oligodendrogliomas. Intraoperative MRI may improve EOR and was associated with increased PFS., (Copyright © 2020 by the Congress of Neurological Surgeons.)
- Published
- 2020
- Full Text
- View/download PDF
4. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.
- Author
-
Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, and Sonabend AM
- Subjects
- Cell- and Tissue-Based Therapy, Humans, Immunotherapy, Glioblastoma genetics, Glioblastoma therapy, Glioma genetics, Glioma therapy
- Abstract
As immunotherapy assumes a central role in the management of many cancers, ongoing work is directed at understanding whether immune-based treatments will be successful in patients with glioblastoma (GBM). Despite several large studies conducted in the last several years, there remain no FDA-approved immunotherapies in this patient population. Nevertheless, there are a range of exciting new approaches being applied to GBM, all of which may not only allow us to develop new treatments but also help us understand fundamental features of the immune response in the central nervous system. In this review, we summarize new developments in the application of immune checkpoint blockade, from biomarker-driven patient selection to the timing of treatment. Moreover, we summarize novel work in personalized immune-oncology by reviewing work in cancer immunogenomics-driven neoantigen vaccine studies. Finally, we discuss cell therapy efforts by reviewing the current state of chimeric antigen receptor T-cell therapy., (© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
5. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.
- Author
-
Fu Y, Liu CJ, Kobayashi DK, Johanns TM, Bowman-Kirigin JA, Schaettler MO, Mao DD, Bender D, Kelley DG, Uppaluri R, Bi WL, Dunn IF, Tao Y, Luo J, Kim AH, and Dunn GP
- Subjects
- Animals, B7-H1 Antigen genetics, B7-H1 Antigen immunology, B7-H1 Antigen metabolism, Brain Neoplasms genetics, Brain Neoplasms metabolism, CD8-Positive T-Lymphocytes immunology, Cell Line, Tumor, GATA2 Transcription Factor genetics, Glioma genetics, Glioma metabolism, Humans, Mice, Programmed Cell Death 1 Ligand 2 Protein genetics, Programmed Cell Death 1 Ligand 2 Protein immunology, Programmed Cell Death 1 Ligand 2 Protein metabolism, Tumor Microenvironment, B7-H1 Antigen biosynthesis, Brain Neoplasms immunology, GATA2 Transcription Factor metabolism, Glioma immunology, Programmed Cell Death 1 Ligand 2 Protein biosynthesis
- Abstract
Encouraging clinical results using immune checkpoint therapies to target the PD-1 axis in a variety of cancer types have paved the way for new immune therapy trials in brain tumor patients. However, the molecular mechanisms that regulate expression of the PD-1 pathway ligands, PD-L1 and PD-L2, remain poorly understood. To address this, we explored the cell-intrinsic mechanisms of constitutive PD-L1 and PD-L2 expression in brain tumors. PD-L1 and PD-L2 expression was assessed by flow cytometry and qRT-PCR in brain tumor cell lines and patient tumor-derived brain tumor-initiating cells (BTICs). Immunologic effects of PD-L2 overexpression were evaluated by IFN-γ ELISPOT. CD274 and PDCD1LG2 cis-regulatory regions were cloned from genomic DNA and assessed in full or by mutating and/or deleting regulatory elements by luciferase assays. Correlations between clinical responses and PD-L1 and PD-L2 expression status were evaluated in TCGA datasets in LGG and GBM patients. We found that a subset of brain tumor cell lines and BTICs expressed high constitutive levels of PD-L1 and PD-L2 and that PD-L2 overexpression inhibited neoantigen specific T cell IFN-γ production. Characterization of novel cis-regulatory regions in CD274 and PDCD1LG2 lead us to identify that GATA2 is sufficient to drive PD-L1 and PD-L2 expression and is necessary for PD-L2 expression. Importantly, in TCGA datasets, PD-L2 correlated with worse clinical outcomes in glioma patients.. By perturbing GATA2 biology, targeted therapies may be useful to decrease inhibitory effects of PD-L2 in the microenvironment.
- Published
- 2020
- Full Text
- View/download PDF
6. A Multi-Institutional Analysis of Factors Influencing Surgical Outcomes for Patients with Newly Diagnosed Grade I Gliomas.
- Author
-
Yahanda AT, Patel B, Sutherland G, Honeycutt J, Jensen RL, Smyth MD, Limbrick DD Jr, Dacey RG Jr, Dowling JL, Dunn GP, Kim AH, Leuthardt EC, Rich KM, Zipfel GJ, Leonard JR, Cahill DP, Shah MV, Abram SR, Evans J, Tao Y, and Chicoine MR
- Subjects
- Adolescent, Adult, Aged, Brain Neoplasms mortality, Brain Neoplasms pathology, Child, Child, Preschool, Female, Glioma mortality, Glioma pathology, Humans, Infant, Intraoperative Care, Kaplan-Meier Estimate, Male, Middle Aged, Neurosurgical Procedures methods, Neurosurgical Procedures mortality, Risk Factors, Treatment Outcome, Young Adult, Brain Neoplasms surgery, Glioma surgery
- Abstract
Objective: To assess the impact of intraoperative magnetic resonance imaging (iMRI), extent of resection (EOR), and other factors on overall survival (OS) and progression-free survival (PFS) for patients with newly diagnosed grade I gliomas., Methods: A multicenter database was queried to identify patients with grade I gliomas. Retrospective analyses assessed the impact of patient, treatment, and tumor characteristics on OS and PFS., Results: A total of 284 patients underwent treatment for grade I gliomas, including 248 resections (205 with iMRI, 43 without), 23 biopsies, and 13 laser interstitial thermal therapy treatments. Log-rank analyses of Kaplan-Meier plots showed improved 5-year OS (P = 0.0107) and PFS (P = 0.0009) with increasing EOR, and a trend toward improved 5-year OS for patients with lower American Society of Anesthesiologists score (P = 0.0528). Greater EOR was associated with significantly increased 5-year PFS for pilocytic astrocytoma (P < 0.0001), but not for ganglioglioma (P = 0.10) or dysembryoplastic neuroepithelial tumor (P = 0.57). Temporal tumors (P = 0.04) and location of "other" (P = 0.04) were associated with improved PFS, and occipital/parietal tumors (P = 0.02) were associated with decreased PFS compared with all other locations. Additional tumor resection was performed after iMRI in 49.7% of cases using iMRI, which produced gross total resection in 64% of these additional resection cases., Conclusions: Patients with grade I gliomas have extended OS and PFS, which correlates positively with increasing EOR, especially for patients with pilocytic astrocytoma. iMRI may increase EOR, indicated by the rate of gross total resection after iMRI use but was not independently associated with increased OS or PFS., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
7. Stereotactic laser ablation of high-grade gliomas.
- Author
-
Hawasli AH, Kim AH, Dunn GP, Tran DD, and Leuthardt EC
- Subjects
- Humans, Stereotaxic Techniques, Brain Neoplasms surgery, Glioma surgery, Laser Therapy methods
- Abstract
Evolving research has demonstrated that surgical cytoreduction of a high-grade glial neoplasm is an important factor in improving the prognosis of these difficult tumors. Recent advances in intraoperative imaging have spurred the use of stereotactic laser ablation (laser interstitial thermal therapy [LITT]) for intracranial lesions. Among other targets, laser ablation has been used in the focal treatment of high-grade gliomas (HGGs). The revived application of laser ablation for gliomas parallels major advancements in intraoperative adjuvants and groundbreaking molecular advances in neuro-oncology. The authors review the research on stereotactic LITT for the treatment of HGGs and provide a potential management algorithm for HGGs that incorporates LITT in clinical practice.
- Published
- 2014
- Full Text
- View/download PDF
8. From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.
- Author
-
Dunn GP, Andronesi OC, and Cahill DP
- Subjects
- Animals, Brain Neoplasms diagnosis, Brain Neoplasms pathology, Genomics, Humans, Brain Neoplasms genetics, Genetic Predisposition to Disease, Glioma genetics, Isocitrate Dehydrogenase genetics, Mutation genetics
- Abstract
The characterization of the genomic alterations across all human cancers is changing the way that malignant disease is defined and treated. This paradigm is extending to glioma, where the discovery of recurrent mutations in the isocitrate dehydrogenase 1 (IDH1) gene has shed new light on the molecular landscape in glioma and other IDH-mutant cancers. The IDH1 mutations are present in the vast majority of low-grade gliomas and secondary glioblastomas. Rapidly emerging work on the consequences of mutant IDH1 protein expression suggests that its neomorphic enzymatic activity catalyzing the production of the oncometabolite 2-hydroxyglutarate influences a range of cellular programs that affect the epigenome, transcriptional programs, hypoxia-inducible factor biology, and development. In the brief time since its discovery, knowledge of the IDH mutation status has had significant translational implications, and diagnostic tools are being used to monitor its expression and function. The concept of IDH1-mutant versus IDH1-wild type will become a critical early distinction in diagnostic and treatment algorithms.
- Published
- 2013
- Full Text
- View/download PDF
9. Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th annual Frye-Halloran Brain Tumor Symposium.
- Author
-
Jones PS, Dunn GP, Barker FG 2nd, Curry WT, Hochberg FH, and Cahill DP
- Subjects
- Brain Neoplasms diagnosis, Brain Neoplasms therapy, Glioma diagnosis, Glioma genetics, Humans, Neoplasm Grading, Neoplasm Recurrence, Local therapy, Prognosis, Brain Neoplasms genetics, Glioma therapy, Mutation genetics, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local genetics, Pathology, Molecular
- Abstract
Object: The authors' goal was to review the current understanding of the underlying molecular and genetic mechanisms involved in low-grade glioma development and how these mechanisms can be targets for detection and treatment of the disease and its recurrence., Methods: On October 4, 2012, the authors convened a meeting of researchers and clinicians across a variety of pertinent medical specialties to review the state of current knowledge on molecular genetic mechanisms of low-grade gliomas and to identify areas for further research and drug development., Results: The meeting consisted of 3 scientific sessions ranging from neuropathology of IDH1 mutations; CIC, ATRX, and FUBP1 mutations in oligodendrogliomas and astrocytomas; and IDH1 mutations as therapeutic targets. Sessions consisted of a total of 10 talks by international leaders in low-grade glioma research, mutant IDH1 biology and its application in glioma research, and treatment., Conclusions: The recent discovery of recurrent gene mutations in low-grade glioma has increased the understanding of the molecular mechanisms involved in a host of biological activities related to low-grade gliomas. Understanding the role these genetic alterations play in brain cancer initiation and progression will help lead to the development of novel treatment modalities than can be personalized to each patient, thereby helping transform this now often-fatal malignancy into a chronic or even curable disease.
- Published
- 2013
- Full Text
- View/download PDF
10. Cancer immunoediting in malignant glioma.
- Author
-
Dunn GP, Fecci PE, and Curry WT
- Subjects
- Animals, Humans, Brain Neoplasms immunology, Cytokines immunology, Glioma immunology, Immunity, Innate immunology, Models, Immunological
- Abstract
Significant work from many laboratories over the last decade in the study of cancer immunology has resulted in the development of the cancer immunoediting hypothesis. This contemporary framework of the naturally arising immune system-tumor interaction is thought to comprise 3 phases: elimination, wherein immunity subserves an extrinsic tumor suppressor function and destroys nascent tumor cells; equilibrium, wherein tumor cells are constrained in a period of latency under immune control; and escape, wherein tumor cells outpace immunity and progress clinically. In this review, we address in detail the relevance of the cancer immunoediting concept to neurosurgeons and neuro-oncologists treating and studying malignant glioma by exploring the de novo immune response to these tumors, how these tumors may persist in vivo, the mechanisms by which these cells may escape/attenuate immunity, and ultimately how this concept may influence our immunotherapeutic approaches.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.